Provision of informed consent prior to any study specific procedures.
Patient should be reviewed as well as confirmed by the National Health Insurance Administration (NHIA) or by the study board member as a Severe Asthma case.
Female and male aged over 18 years old.
Patients who are treated either with omalizumab, mepolizumab, or benralizumab after January 1, 2020.
You may not be if
Lack of informed consent for participation.
History of Biologic usage before January 1, 2020, should be ruled out.
The washout period should be at least 12 months. In other words, the enrolled patients should have no experience in receiving a biological treatment or in participating relative clinical trial before his/her biologic initiation.
Comorbid pulmonary diseases (e.g.: Chronic Obstructive Pulmonary Disease, Bronchiectasis, Pulmonary Fibrosis, etc.) or risk factors (e.g.: smoking or environmental exposure, etc..) that could be associated with pulmonary or systemic diseases, other than Asthma.
Clareo Health | Taiwan Severe Asthma Biologic Registry
